Citadel Advisors’s Akcea Therapeutics Inc AKCA Stock Holding History

Citadel Advisors’s Portfolio AKCA Stock Details AKCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-49,300	Closed	-$759K	–	10085
2019 Q3	$759K	Sell	49,300 -18,000	-27%	-$383K	﹤0.01%	6070
2019 Q2	$1.58M	Sell	67,300 -500	-0.7%	-$12.4K	﹤0.01%	4928
2019 Q1	$1.92M	Sell	67,800 -34,100	-33%	-$993K	﹤0.01%	4535
2018 Q4	$3.07M	Sell	101,900 -4,900	-5%	-$137K	﹤0.01%	3484
2018 Q3	$3.74M	Buy	106,800 +70,400	+193%	+$2.13M	﹤0.01%	3385
2018 Q2	$863K	Buy	36,400 +15,800	+77%	+$377K	﹤0.01%	5474
2018 Q1	$528K	Buy	+20,600	New	+$443K	﹤0.01%	5793

Citadel Advisors's AKCA Position: Q4 2020 in Review

Citadel Advisors sold out of Akcea Therapeutics Inc (AKCA) in Q4 2020, closing a stake of 25,890 shares — an estimated $470K sold.

Citadel Advisors first reported a position in AKCA in Q2 2018 and held it in 10 quarters. The position peaked at $17.8M in Q1 2019. 0 funds tracked by Wall St. Rank hold AKCA as of Q4 2020.

Citadel Advisors reported no remaining Akcea Therapeutics Inc position as of Q4 2020 after selling out during the quarter.
Citadel Advisors sold 25,890 Akcea Therapeutics Inc shares in Q4 2020, an estimated $470K.
Citadel Advisors first reported a position in Akcea Therapeutics Inc in Q2 2018 and held it in 10 quarters.
Citadel Advisors's Akcea Therapeutics Inc position peaked at $17.8M in Q1 2019.
0 funds tracked by Wall St. Rank held Akcea Therapeutics Inc as of Q4 2020.

Based on Citadel Advisors's 13F filing for Q4 2020, filed 16 Feb 2021.